IP Library Granted Patent US 10,301,612
Granted Patent B2
US 10,301,612 · App. 15/880,029 · Granted May 28, 2019

Recombinant elastase proteins and methods of manufacturing and use thereof

Inventors: F. Nicholas Franano (Kansas City, MO); Kimberly Bland (Kansas City, MO); Marco D. Wong (Overland Park, KS); Bee C. Ding (Overland Park, KS)
Assignee: PROTEON THERAPEUTICS, INC.
C12N9/6448A61K9/19A61K38/486C07K1/14C12N9/50C12N15/815C12P21/02C12Y304/21036A61K38/00C07K2319/00C07K2319/02C07K2319/50C12Y304/21037
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,301,612
App. No.
15/880,029
Granted
May 28, 2019
Kind
B2
Abstract

The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention.

Claims (28)

1. An autoactivating type I pancreatic proelastase protein comprising an amino acid sequence which is at least 90% identical to a reference amino acid sequence consisting of SEQ ID NO:73 linked at its C-terminus to the N-terminus of SEQ ID NO:1, wherein the first thirteen amino acids of the reference amino acid sequence are P10-P9-P8-P7-P6-P5-P4-P3-P2-P1-P1′-P2′-P3′, and wherein:

(a) the amino acid residues at the P10-P5 and P1′-P3′ positions in the protein are each independently selected from any natural amino acid;

(b) the amino acid residue at the P4 position in the protein is any natural amino acid except glycine, lysine, phenylalanine, tyrosine, tryptophan, or arginine;

(c) the amino acid residue at the P3 position in the protein is any natural amino acid except proline or glycine;

(d) the amino acid residue at the P2 position in the protein is proline, alanine, leucine, isoleucine, glycine, valine, histidine, or threonine; and

(e) the amino acid residue at the P1 position in the protein is alanine, leucine, valine, isoleucine, or serine.

2. The autoactivating type I pancreatic proelastase protein of claim 1 , wherein:

(a) the amino acid residue at the P5 position in the protein is glutamate, histidine, proline, glycine, asparagine, lysine, or alanine;

(b) the amino acid residue at the P4 position in the protein is threonine, alanine, proline, or histidine;

(c) the amino acid residue at the P3 position in the protein is alanine, leucine, isoleucine, methionine, lysine, asparagine, or valine;

(d) the amino acid residue at the P2 position in the protein is proline, alanine, leucine, isoleucine, glycine, valine, or threonine; and

(e) the amino acid residue at the P1 position in the protein is alanine, leucine, valine, isoleucine, or serine.

3. The autoactivating type I pancreatic proelastase protein of claim 1 , wherein the amino acid residue at the P5 position in the protein is histidine.

4. The autoactivating type I pancreatic proelastase protein of claim 1 , wherein the amino acid residue at the P4 position in the protein is threonine.

5. The autoactivating type I pancreatic proelastase protein of claim 1 , wherein the amino acid residue at the P3 position in the protein is asparagine.

6. The autoactivating type I pancreatic proelastase protein of claim 1 , wherein the amino acid residue at the P2 position in the protein is proline.

7. The autoactivating type I pancreatic proelastase protein of claim 1 , wherein the amino acid residue at the P1 position in the protein is alanine.

8. The autoactivating type I pancreatic proelastase protein of claim 1 , wherein the amino acid residues at the P3-P1 positions in the protein have the amino acid sequence of SEQ ID NO:20.

9. The autoactivating type I pancreatic proelastase protein of claim 1 , wherein the amino acid residues at the P10-P1 positions in the protein have the amino acid sequence of SEQ ID NO:73.

10. The autoactivating type I pancreatic proelastase protein of claim 1 , wherein the amino acid residues at the P10-P3′ positions in the protein have the amino acid sequence of SEQ ID NO:55.

11. The autoactivating type I pancreatic proelastase protein of claim 1 , wherein the protein comprises an amino acid sequence which is at least 95% identical to the reference amino acid sequence.

12. The autoactivating type I pancreatic proelastase protein of claim 1 , wherein the protein comprises an amino acid sequence which is at least 99% identical to the reference amino acid sequence.

13. The autoactivating type I pancreatic proelastase protein of claim 1 , wherein the protein comprises an amino acid sequence which is identical to the reference amino acid sequence.

14. The autoactivating type I pancreatic proelastase protein of claim 1 , which further comprises a signal sequence.

15. The autoactivating type I pancreatic proelastase protein of claim 1 , which is isolated.

16. The autoactivating type I pancreatic proelastase protein of claim 1 , wherein the autoactivating type I pancreatic proelastase protein produces a mature type I pancreatic elastase having elastase activity following autoactivation.

17. The autoactivating type I pancreatic proelastase protein of claim 1 , wherein the autoactivating type I pancreatic proelastase protein comprises a cleavage site that is cleaved by a mature type I pancreatic elastase having elastase activity.

18. The autoactivating type I pancreatic proelastase protein of claim 1 , wherein autoactivation of the type I pancreatic proelastase protein produces a mature type I pancreatic elastase having elastase activity.

Assignments (3)
CHANGE OF NAME Recorded Nov 30, 2020
From: ARTARA THERAPEUTICS, INC.
To: PROTARA THERAPEUTICS, INC.
Reel/Frame 054553/0688 →
MERGER Recorded Nov 18, 2020
From: PROTEON THERAPEUTICS, INC.
To: ARTARA THERAPEUTICS, INC.
Reel/Frame 054476/0140 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2020
From: FRANANO, F. NICHOLAS; BLAND, KIMBERLY S.; WONG, MARCO D.; DING, BEE C.
To: PROTEON THERAPEUTICS, INC.
Reel/Frame 054381/0318 →
Continuity (2)
Continuation 12823098 · Jun 24, 2010
Related Publication 20180155703A1 · Jun 7, 2018